The relevance of NLRP3 and IL-1ß in cancer progression and cancer therapy-related (cardiac) detrimental effects form the rationale of several clinical trials currently investigating the efficacy of anti-IL-1ß drugs, mainly the IL-1ß antagonist canakinumab and the natural anti-ILR antagonist, anakinra, as anti-cancer therapy alone, or in combination with CAR T cells or the checkpoint inhibitors anti-PD1 or anti-PDL1 (40). Here, NLRP3 is linked to cancer.